MEDYSN is a translational neuroscience and biotechnology company focused on solving neglected clinical challenges through precision innovation.
We develop high impact, clinically viable solutions that larger players often overlook, including noninvasive neuromodulation technologies, next generation therapeutics, advanced pharmaceutical manufacturing, diagnostics, and precision delivery systems.
Our mission is to close the gap between unmet medical needs and frontier science. Through interdisciplinary R&D, strategic partnerships, and a patient first mindset, we turn bold hypotheses into real world breakthroughs.
MEDYSN operates at the intersection of neuroscience, biotechnology, and clinical care, where innovation meets urgency.
For partnership or research inquiries, contact Dylan at dylan@medysn.com.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Houston, Tx 77389, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Translational Neuroscience, Neuromodulation, Neurotechnology, Regenerative Medicine, Drug Repurposing & Reformulation, Pharmaceutical Manufacturing, Biotech Device Development, Precision Dosing & Pharmacogenomics, AI-Driven Drug Discovery, Closed-Loop Systems & Feedback Interfaces, Osteoporosis Innovation, Appetite Regulation & Metabolic Disorders, Space & Zero-Gravity Medicine.
- HQ
- Houston, TX
Medysn Questions
Medysn's LinkedIn profile is https://www.linkedin.com/company/medysn
Medysn has
1 employees.
View email and phone details for 1
employees at Medysn.
Medysn's industry is
Biotechnology Research
Medysn's top competitors are
Cellenkos, Inc.,
Gpg Ventures - Houston,
Innosign,
Aulos Bioscience,
Clicksculpt,
Bonvexa,
Afyx Therapeutics A/s,
8 Billion Project,
Gnova Biotech,
Xeia Venture Partners.
Medysn's categories are Biotechnology Research
Medysn's founding year is 2024
